WTX-212 is under clinical development by West Lake Biomedical Technology (Hangzhou) and currently in Phase I for Primary Mediastinal B-Cell Lymphoma. According to GlobalData, Phase I drugs for Primary Mediastinal B-Cell Lymphoma have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how WTX-212’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

WTX-212 overview

WTX-212  is under development for the treatment of lung cancer, Hodgkin lymphoma (cHL), primary mediastinal large B-cell lymphoma PMBCL , extranodal NK/T-cell lymphoma ENKTCL, mycosis fungoides/Sezari syndrome MF/SS. The therapy comprises of autologous engineered red blood cells administered as infusion, it is being developed based on red blood cell drug technology platform REDx. It acts by expressing serine protein kinase B-Raf-g469v mutated protein.

West Lake Biomedical Technology (Hangzhou) overview

Westlake Therapeutics a developer of cell therapy intended to treat diseases through cellular medicine, a cell therapy company. It is headquartered in Hangzhou City, Zhejiang, China.

For a complete picture of WTX-212’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.